The Maharashtra Food & Drug Administration has ordered Patanjali Foods Limited to recall and stop selling its "Patanjali Karela Jamun Juice". The regulatory notice alleges that the product's marketing claims violate the Drugs and Magic Remedies Act, requiring the company to submit a compliance report within 15 days.
NAGPUR — The Food & Drug Administration (FDA) of Maharashtra State has issued an official notice to Patanjali Foods Limited, ordering an immediate recall and halt in sales of its "Patanjali Karela Jamun Juice".
The regulatory directive, issued by the Joint Commissioner (Drugs) for the Nagpur Division, was received by the company on June 8, 2026. The enforcement action follows an official review of the product's marketing materials. Regulators allege that the product's labelling and promotional claims violate federal laws governing objectionable medical advertisements. This development marks another instance of heightened regulatory scrutiny facing India's prominent consumer wellness and ayurvedic manufacturing sector.
Alleged Violations Under the Drugs and Magic Remedies Act
The statutory intervention centers entirely on the promotional, labelling, advertising, and marketing representations printed on the packaging of Patanjali Karela Jamun Juice. According to Patanjali Foods' compliance filing with the stock exchanges, the Nagpur Division of the FDA determined that certain health claims made by the product fall within the scope of diseases and conditions prohibited under the Schedule of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 (DMR Act).
The DMR Act is designed to prevent consumer electronics, food products, or alternative medicines from claiming to prevent, treat, or cure specific chronic medical conditions, such as diabetes or kidney disorders, without appropriate pharmaceutical licensing. The Joint Commissioner has formally called upon Patanjali Foods to explain why the restrictive provisions of Sections 3 and 4 of the DMR Act should not apply to its current branding strategies.
Scope of Mandatory Enforcement Measures and Recall Mandate
Pending a detailed review of Patanjali Foods’ legal justifications, the Maharashtra FDA has imposed a series of strict administrative restrictions. These measures are aimed at protecting consumers from potentially misleading therapeutic claims:
Product Recall: Patanjali Foods must execute an immediate commercial recall of existing batches of Patanjali Karela Jamun Juice from wholesale and retail channels.
Discontinuation of Sales: The company has been ordered to completely halt all distribution, supply, and marketplace sales of the product until the identified statutory concerns are resolved.
Branding Withdrawal: Management must immediately withdraw or modify all offending promotional materials, advertisements, and product labels.
Compliance Window: The regulator requires Patanjali Foods to submit an official compliance report detailing its corrective actions within 15 days of receiving the notice.
Corporate Assessment and Financial Impact
In a prompt disclosure filed on June 9, 2026, with both BSE Limited and the National Stock Exchange of India Limited (NSE), Patanjali Foods confirmed it is reviewing the communication in consultation with its legal advisors. The notification was submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company's management assured investors that the regulatory notice would not result in operational disruptions for the broader group.
Official Sources Section
The corporate updates and regulatory enforcement parameters detailed in this report are based directly on formal disclosures:
The material legal notice parameters follow the statutory filing signed by Ramji Lal Gupta, Company Secretary of Patanjali Foods Limited.
Public market alerts were retrieved from the corporate disclosure repositories of
BSE Limited(Scrip Code: 500368) and the National Stock Exchange of India Limited (Symbol: PATANJALI).The disclosure structure complies with SEBI Circular No. SEBI/HO/CFD/CFD-POD-2/P/CIR/2025/25 and the updated SEBI Master Circular dated January 30, 2026.
All corporate parameters are detailed in the official company compliance file labeled "HexacomApril20_09062026161306_Reg30.pdf".
Executive Position on Regulatory Compliance
Patanjali Foods' compliance desk stated that the corporation is formulating a defense but will strictly comply with local consumer protection laws while doing so.
"The Company is currently reviewing the contents of the communication in consultation with its legal advisors and is in the process of formulating an appropriate response," stated Ramji Lal Gupta, Company Secretary of Patanjali Foods Limited, in the official filing. "The Company will take all necessary actions in accordance with applicable law and regulatory requirements."
Why It Matters to Consumers and Retail Investors
For health-conscious consumers, this regulatory action highlights the government's strict oversight of label claims on wellness products. For retail investors, the notice poses minimal threat to Patanjali Foods’ broader financials, as the production freeze applies only to a single product line rather than its major edible oil or core packaged food segments. However, the recall underscores the ongoing compliance risks that alternative healthcare brands face when navigating medical advertisement laws in India.
Key Facts at a Glance
Targeted Product: The FDA recall is directed specifically at "Patanjali Karela Jamun Juice" batches.
Regulatory Authority: The enforcement action was initiated by the Joint Commissioner (Drugs) of the Maharashtra FDA's Nagpur Division.
Legal Basis: Regulators invoked the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Zero Fines: No upfront monetary penalties or structural sanctions have been levied against the listed company.
Response Clock: The manufacturer has 15 days from receipt to file a formal compliance report.
FAQ Section
Why was the sale of Patanjali Karela Jamun Juice halted?
The Maharashtra FDA halted sales because certain promotional and labelling claims on the product may violate the Drugs and Magic Remedies Act by implying unauthorized benefits for specific diseases.
Will this enforcement action impact Patanjali Foods financially?
According to Patanjali Foods' preliminary assessment, the recall and temporary product suspension are not expected to have a material financial impact on the company's overall business operations.
What must Patanjali do to resume selling the product?
The company must address the FDA's concerns, withdraw or modify the objectionable labels, and submit a satisfactory compliance report within the mandatory 15-day window.
Source: National Stock Exchange of India Investor Portal, BSE Limited Corporate Disclosure Platform
